4J. D. Ringe,A. Dorst,H. Faber,K. Ibach. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study[J] 2004,Rheumatology International(2):110～113
5S. Gonnelli,C. Cepollaro,A. Montagnani,D. Bruni,C. Caffarelli,M. Breschi,L. Gennari,C. Gennari,R. Nuti. Alendronate Treatment in Men With Primary Osteoporosis: A Three-Year Longitudinal Study[J] 2003,Calcified Tissue International(2):133～139
6A. Trombetti,F. Herrmann,P. Hoffmeyer,M. A. Schurch,J. P. Bonjour,R. Rizzoli. Survival and Potential Years of Life Lost After Hip Fracture in Men and Age-matched Women[J] 2002,Osteoporosis International(9):731～737
7T. W. O’Neill,C. Cooper,J. D. Finn,M. Lunt,D. Purdie,D. M. Reid,R. Rowe,A. D. Woolf,W. A. Wallace. Incidence of Distal Forearm Fracture in British Men and Women[J] 2001,Osteoporosis International(7):555～558
8J. Huuskonen,S. B. V?is?nen,H. Kr?ger,C. Jurvelin,C. Bouchard,E. Alhava,R. Rauramaa. Determinants of Bone Mineral Density in Middle Aged Men: A Population-Based Study[J] 2000,Osteoporosis International(8):702～708
9Y. V. Ho,A. G. Frauman,W. Thomson,E. Seeman. Effects of Alendronate on Bone Density in Men with Primary and Secondary Osteoporosis[J] 2000,Osteoporosis International(2):98～101
10L. J. Melton III,E. J. Atkinson,C. Cooper,W. M. O’Fallon,B. L. Riggs. Vertebral Fractures Predict Subsequent Fractures[J] 1999,Osteoporosis International(3):214～221
5Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women[ J]. J Am Med Assoc, 2002, 288(3) : 321 -333.
6Eriksen EF. Hormone replacement therapy or SERMS in the long term treatment of osteoporosis [ J ]. Minerva Ginecol, 2012, 64 (3) : 207 -221.
7Deliras PD, Ehsrud KE, Adachi SD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopusal women with osteoporosis four - year results from a randanized clinical trial[ J ]. J Clin Endocrinol Metab, 2002, 87(8) : 3609 -3617.
8Nelson ER, Wardell SE, McDonnell DP. The molecular mecha- nisms underlying the pharmacological actions of estrogens, SERMs and oxysterols : implications for the treatment and prevention of os- teoporosis[J]. Bone, 2013, 53(1): 42-50.
9Calaf Alsina J, Coronado Martin PJ. Third generation selective es- trogen receptor modulators : benefits beyond bone [ J ]. Med Clin (Barc), 2013, 140(6) : 266 -271.
10Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in post- menopausal women with osteoporosls[ J]. N Engl J Mad, 2010, 362 ( 8 ) : 686 - 696.
